Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
Addressing Drug Resistance in Non-Small Cell Lung Cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All news
Data & publication
High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma
Data & publication
Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
Press coverage
MedNous – Small company, big theme: How iOnctura is pursuing drug resistance
Press release
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
Press coverage
Endpoints News – iOnctura raises €80M to advance early-stage rare eye cancer treatment
Press coverage
FirstWord Pharma – With fresh €80M in hand, iOnctura looks to chart new PI3K path
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Data & publication
Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Data & publication
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Data & publication
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Data & publication
Preclinical activity of novel TGF beta receptor I kinase Inhibitors IOA-359 and IOA-360 for treatment of anemia in MDS/AML
Looking for media
resources?